Class information for:
Level 1: PCSK9//PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9//ALIROCUMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
9366 1162 43.2 87%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
171 3       MONASCUS//CITRININ//MONASCUS PURPUREUS 58457
419 2             STATINS//EZETIMIBE//SIMVASTATIN 16502
9366 1                   PCSK9//PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9//ALIROCUMAB 1162

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PCSK9 authKW 4863097 21% 74% 249
2 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 authKW 1917453 8% 81% 90
3 ALIROCUMAB authKW 985360 4% 83% 45
4 PCSK9 INHIBITORS authKW 583964 3% 67% 33
5 EVOLOCUMAB authKW 493403 2% 72% 26
6 PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 authKW 341597 1% 100% 13
7 BIOCHEM NEUROENDOCRINOL address 286006 5% 21% 53
8 PROPROTEIN CONVERTASE SUBTILISIN authKW 234091 1% 64% 14
9 AMG 145 authKW 210213 1% 100% 8
10 LOW DENSITY LIPOPROTEIN CHOLESTEROL authKW 209300 7% 10% 79

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Cardiac & Cardiovascular System 8573 34% 0% 396
2 Peripheral Vascular Diseases 3867 17% 0% 202
3 Medicine, General & Internal 679 13% 0% 146
4 Biochemistry & Molecular Biology 472 20% 0% 238
5 Pharmacology & Pharmacy 335 12% 0% 143
6 Endocrinology & Metabolism 329 8% 0% 89
7 Medicine, Research & Experimental 100 5% 0% 54
8 Hematology 97 4% 0% 42
9 Medical Laboratory Technology 91 2% 0% 20
10 Nutrition & Dietetics 75 3% 0% 32

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BIOCHEM NEUROENDOCRINOL 286006 5% 21% 53
2 CARBOHYDRATE LIPID METAB UNIT 114430 1% 31% 14
3 UNIT CARDIAC CARDIOVASC GENET 88502 1% 42% 8
4 HLTH POLICY QUAL INFORMAT PROGRAM 80071 1% 38% 8
5 DEV LAUNCH UNIT PCSK9 78830 0% 100% 3
6 ENDOCRINOL METABCLIN 78830 0% 100% 3
7 DYSLIPIDEMIASTATE CARDIOVASC DIS 77270 1% 29% 10
8 SOC ITALIANA STUDIO ATEROSCLEROSI 55637 1% 35% 6
9 SECT CARDIOVASC 54221 1% 13% 16
10 BARBRA STREISAND WOMENS HEART HLTH PROGRAM 52553 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF CLINICAL LIPIDOLOGY 55273 3% 6% 37
2 CURRENT OPINION IN LIPIDOLOGY 15505 2% 2% 28
3 ATHEROSCLEROSIS 12776 6% 1% 72
4 CURRENT ATHEROSCLEROSIS REPORTS 8915 1% 2% 15
5 CLINICAL LIPIDOLOGY 6859 1% 3% 10
6 JOURNAL OF LIPID RESEARCH 5391 4% 0% 42
7 AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 5038 1% 2% 9
8 ATHEROSCLEROSIS SUPPLEMENTS 4635 1% 3% 7
9 LIPIDS IN HEALTH AND DISEASE 3891 1% 1% 15
10 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 3050 4% 0% 43

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PCSK9 4863097 21% 74% 249 Search PCSK9 Search PCSK9
2 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 1917453 8% 81% 90 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9
3 ALIROCUMAB 985360 4% 83% 45 Search ALIROCUMAB Search ALIROCUMAB
4 PCSK9 INHIBITORS 583964 3% 67% 33 Search PCSK9+INHIBITORS Search PCSK9+INHIBITORS
5 EVOLOCUMAB 493403 2% 72% 26 Search EVOLOCUMAB Search EVOLOCUMAB
6 PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 341597 1% 100% 13 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+9
7 PROPROTEIN CONVERTASE SUBTILISIN 234091 1% 64% 14 Search PROPROTEIN+CONVERTASE+SUBTILISIN Search PROPROTEIN+CONVERTASE+SUBTILISIN
8 AMG 145 210213 1% 100% 8 Search AMG+145 Search AMG+145
9 LOW DENSITY LIPOPROTEIN CHOLESTEROL 209300 7% 10% 79 Search LOW+DENSITY+LIPOPROTEIN+CHOLESTEROL Search LOW+DENSITY+LIPOPROTEIN+CHOLESTEROL
10 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PCSK9 198711 1% 69% 11 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9+PCSK9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9+PCSK9

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 SCHULZ, R , SCHLUTER, KD , LAUFS, U , (2015) MOLECULAR AND CELLULAR FUNCTION OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9).BASIC RESEARCH IN CARDIOLOGY. VOL. 110. ISSUE 2. P. - 166 95% 10
2 SEIDAH, NG , AWAN, Z , CHRETIEN, M , MBIKAY, M , (2014) PCSK9: A KEY MODULATOR OF CARDIOVASCULAR HEALTH.CIRCULATION RESEARCH. VOL. 114. ISSUE 6. P. 1022 -1036 104 79% 92
3 LAMBERT, G , SJOUKE, B , CHOQUE, B , KASTELEIN, JJP , HOVINGH, GK , (2012) THE PCSK9 DECADE.JOURNAL OF LIPID RESEARCH. VOL. 53. ISSUE 12. P. 2515 -2524 91 95% 123
4 BERGERON, N , PHAN, BAP , DING, YC , FONG, A , KRAUSS, RM , (2015) PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITION A NEW THERAPEUTIC MECHANISM FOR REDUCING CARDIOVASCULAR DISEASE RISK.CIRCULATION. VOL. 132. ISSUE 17. P. 1648 -1666 106 79% 26
5 ABIFADEL, M , ELBITAR, S , EL KHOURY, P , GHALEB, Y , CHEMALY, M , MOUSSALLI, ML , RABES, JP , VARRET, M , BOILEAU, C , (2014) LIVING THE PCSK9 ADVENTURE: FROM THE IDENTIFICATION OF A NEW GENE IN FAMILIAL HYPERCHOLESTEROLEMIA TOWARDS A POTENTIAL NEW CLASS OF ANTICHOLESTEROL DRUGS.CURRENT ATHEROSCLEROSIS REPORTS. VOL. 16. ISSUE 9. P. - 107 93% 24
6 NORATA, GD , TIBOLLA, G , CATAPANO, AL , (2014) TARGETING PCSK9 FOR HYPERCHOLESTEROLEMIA.ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54. VOL. 54. ISSUE . P. 273-293 99 96% 19
7 LIPINSKI, MJ , BENEDETTO, U , ESCARCEGA, RO , BIONDI-ZOCCAI, G , LHERMUSIER, T , BAKER, NC , TORGUSON, R , BREWER, HB , WAKSMAN, R , (2016) THE IMPACT OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 SERINE PROTEASE INHIBITORS ON LIPID LEVELS AND OUTCOMES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA: A NETWORK META-ANALYSIS.EUROPEAN HEART JOURNAL. VOL. 37. ISSUE 6. P. 536 -U103 36 86% 38
8 CARIOU, B , LE MAY, C , COSTET, P , (2011) CLINICAL ASPECTS OF PCSK9.ATHEROSCLEROSIS. VOL. 216. ISSUE 2. P. 258 -265 77 94% 64
9 NORATA, GD , TAVORI, H , PIRILLO, A , FAZIO, S , CATAPANO, AL , (2016) BIOLOGY OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9: BEYOND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING.CARDIOVASCULAR RESEARCH. VOL. 112. ISSUE 1. P. 429 -442 94 68% 3
10 NORATA, GD , TIBOLLA, G , CATAPANO, AL , (2014) PCSK9 INHIBITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: PROMISES AND EMERGING CHALLENGES.VASCULAR PHARMACOLOGY. VOL. 62. ISSUE 2. P. 103 -111 77 90% 14

Classes with closest relation at Level 1


Rank Class id link
1 3640 FAMILIAL HYPERCHOLESTEROLEMIA//FAMILIAL HYPERCHOLESTEROLAEMIA//LOW DENSITY LIPOPROTEIN RECEPTOR
2 18626 PITAVASTATIN//NK 104//CAS 147526 32 7
3 13608 EZETIMIBE//NPC1L1//CHOLESTEROL ABSORPTION INHIBITOR
4 12208 FRIEDEWALD FORMULA//NON HDL CHOLESTEROL//NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL
5 7604 CORONARY HEART DISEASE RISK FUNCTIONS//FRAMINGHAM//REGICOR
6 413 STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN
7 7494 STATINS//RHABDOMYOLYSIS//STATIN INTOLERANCE
8 2661 HIGH DENSITY LIPOPROTEIN//HDL//REVERSE CHOLESTEROL TRANSPORT
9 9236 9P21//CHROMOSOME 9P21//CIRCULATION-CARDIOVASCULAR GENETICS
10 8938 SREBP//SCAP//STEROL REGULATORY ELEMENT BINDING PROTEIN

Go to start page